ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2.
APA
Bai M, Gao Q, et al. (2026). ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2.. Molecular cancer. https://doi.org/10.1186/s12943-026-02653-2
MLA
Bai M, et al.. "ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2.." Molecular cancer, 2026.
PMID
41928228
같은 제1저자의 인용 많은 논문 (5)
- Identification of altered immune landscape at single-cell resolution in NSCLC brain metastasis and its association with poor immune checkpoint inhibitor responses.
- Comprehensive Analysis of the Expression and Prognostic Significance of NPAS1 in Patients with Colorectal Adenocarcinoma Based on Bioinformatics.
- An anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) and chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib study.
- A Polysaccharide-Based Fluorescent Polymer Carrier for Natural Product Delivery and Gastric Cancer Inhibition.
- Lung cancer and COVID-19 susceptibility and severity: a Mendelian randomization analysis.